Dana-Farber Cancer Institute
This study is looking to learn whether a tumor testing approach can feasibly measure antibody-drug conjugate (ADC) target proteins in children and young adults with relapsed or refractory solid tumors or central nervous system (CNS) tumors. The tumor testing approach is a two-step tumor profiling process of: * Screening with bulk RNA sequencing to see which ADC target genes are turned on in the tumor. * Confirmatory immunohistochemistry (IHC) for targets that show positive expression on the RNA screen, to confirm protein expression.
This is a non-therapeutic feasibility study evaluating the prospective measurement of antibody-drug conjugate (ADC) target antigen expression in pediatric patients with relapsed or refractory solid or CNS tumors. The study aims to characterize ADC antigen expression patterns, compare expression at diagnosis and relapse, and describe real-world utilization and outcomes of ADCs in pediatric tumors. Participants will be enrolled into two cohorts: a prospective cohort and a retrospective cohort. The prospective cohort will undergo eligibility screening, enrollment, specimen submission, bulk RNA…
Inclusion Criteria: Inclusion Criteria for Prospective Cohort * Age 0 - 30 years at time of initial diagnosis of the solid or CNS tumor * Diagnosis of relapsed or refractory solid or CNS tumor, without a limit on the number of prior episodes of relapse. Refractory disease is defined as disease that progresses on standard-of-care upfront therapy or requires salvage therapy due to inadequate response, e.g. bridging chemoimmunotherapy in a patient with high-risk neuroblastoma and poor end-induction response (PEIR). * Life expectancy of at least 12 weeks at the time of enrollment * Available spe…
Test performed on tumor tissue to measure antibody-drug conjugate (ADC) target expression
Test performed on tumor tissue to confirm protein expression of antibody-drug conjugate (ADC) target antigens identified by bulk RNA sequencing
Arctuva estimate
Verify or correct the compensation shown for this listing.